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Background In 1997, The Gambia introduced three primary doses of 
Haemophilus influenzae type b (Hib) conjugate vaccine without a boost-
er in its infant immunisation programme along with establishment of a 
population-based surveillance on Hib meningitis in the West Coast Re-
gion (WCR). This surveillance was stopped in 2002 with reported elimi-
nation of Hib disease. This was re-established in 2008 but stopped again 
in 2010. We aimed to re-establish the surveillance in WCR and to con-
tinue surveillance in Basse Health and Demographic Surveillance System 
(BHDSS) in the east of the country to assess any shifts in the epidemiolo-
gy of Hib disease in The Gambia.
Methods In WCR, population-based surveillance for Hib meningitis was 
re-established in children aged under-10 years from 24 December 2014 
to 31 March 2017, using conventional microbiology and Real Time Poly-
merase Chain Reaction (RT-PCR). In BHDSS, population-based surveil-
lance for Hib disease was conducted in children aged 2-59 months from 
12 May 2008 to 31 December 2017 using conventional microbiology only. 
Hib carriage survey was carried out in pre-school and school children from 
July 2015 to November 2016.
Results In WCR, five Hib meningitis cases were detected using conven-
tional microbiology while another 14 were detected by RT-PCR. Of the 
19 cases, two (11%) were too young to be protected by vaccination while 
seven (37%) were unvaccinated. Using conventional microbiology, the in-
cidence of Hib meningitis per 100 000-child-year (CY) in children aged 
1-59 months was 0.7 in 2015 (95% confidence interval (CI) = 0.0-3.7) 
and 2.7 (95% CI = 0.7-7.0) in 2016. In BHDSS, 25 Hib cases were report-
ed. Nine (36%) were too young to be protected by vaccination and five 
(20%) were under-vaccinated for age. Disease incidence peaked in 2012-
2013 at 15 per 100 000 CY and fell to 5-8 per 100 000 CY over the sub-
sequent four years. The prevalence of Hib carriage was 0.12% in WCR 
and 0.38% in BHDSS.
Conclusions After 20 years of using three primary doses of Hib vaccine 
without a booster Hib transmission continues in The Gambia, albeit at low 
rates. Improved coverage and timeliness of vaccination are of high priori-
ty for Hib disease in settings like Gambia, and there are currently no clear 
indications of a need for a booster dose.
Following the introduction of Haemophilus influenzae type b (Hib) conjugate 
vaccine (HCV) in many countries, there has been a substantial decline in deaths 
due to Hib disease globally (approximately 90%) with an estimated 299 000 
deaths in 2000 and 29 500 in 2015 [1]. In 1997, The Gambia became the first 
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African country to introduce HCV (Hib polysaccharide-tetanus toxoid conjugate 
vaccine) (PRP-T; Act-Hib, supplied by Pasteur Mérieux, Lyon, France) in its Ex-
panded Programme on Immunisation (EPI) with three primary doses scheduled 
at 2, 3, and 4 months of age [2]. Although the specific HCV has changed over 
time, there has not been changes in the programme of administering three pri-
mary doses without a booster. The programme had substantial impact with no 
Hib disease recorded in 2002 with a dramatic decline in Hib carriage from 12% 
in 1997 to 0.25% in 2002 [2]. However, ongoing low incidence of the disease 
was reported in the West Coast Region (WCR) of The Gambia from July 2005 
to April 2006 [3] and from 2008 to 2010 [4]. A resurgence of the disease was 
then noted in 2012-2013 as part of formal surveillance in the Basse Health and 
Demographic Surveillance System (BHDSS) in the rural east of the country [5]. 
In an earlier study among fully vaccinated children in The Gambia, Hib anti-
body concentrations were found to be 22% (95% CI = 4%-36%) lower in chil-
dren 3 to <5 years age group compared to those in the 1 to <2 years age group 
[4]. Waning antibody concentrations with temporary increase in Hib disease 
incidence following several years of three primary doses without a booster was 
reported from other countries such as the UK and Mexico [6-8]. The resurgence 
in BHDSS, incidental disease in WCR and waning immunity in older children 
[4] that occurred in populations with high vaccine coverage [9] raised the ques-
tion of the need for a booster dose and reinforced the need for continued sur-
veillance [1]. Among African countries, The Gambia is well-placed to address 
these questions as it consistently used the same standardised methods of pop-
ulation-based surveillance of Hib disease and carriage for the longest period of 
time (periodically for over past 28 years beginning in 1990). In this study we 
aimed to: a. enhance Hib meningitis surveillance in WCR to obtain data com-
parable to historical Hib surveillance; b. continue surveillance for Hib disease 
in BHDSS to assess the state of disease control following the recent upsurge; c. 
measure the incidence of Hib disease overall and by age group; and d. under-
take carriage studies in key age groups to detect potential reservoirs for increased 
transmission. These studies would assess any shifts in the epidemiology of Hib 
disease that could suggest a change in Hib vaccination policy in The Gambia 
or in other similar settings.
METHODS
Setting
The WCR on the Atlantic coast is mainly urban and peri-urban with a few small 
rural communities (Figure 1). It had a population of 168 898 aged under 5 years 
and 310 338 under 10 years in 2013 (Personal communication, The Gambia 
Bureau of Statistics, 2014). The coverages of three doses of the Hib containing 
pentavalent vaccine among children 12-23 months of age from 2014 to 2017 
were 96%, 97%, 95%, and 92%, respectively [9].
The BHDSS was established on the southern bank of the River Gambia in 2007 
(Figure 1) in the most eastern part of the country where the Medical Research 
Council Unit, The Gambia at the London School of Hygiene & Tropical Medi-
cine (MRCG) operates a Field Station. The estimated population under 5 years 
of age was 34 658 in 2013 and is enumerated every four months. Basse Dis-
trict Hospital is the main health facility and receives referrals from five smaller 
health facilities in the area. There are no private inpatient facilities in the area.
Surveillance in WCR
We carried out surveillance for Hib meningitis in WCR from 24 December 
2014 to 31 March2017. The previous surveillance was carried out in the same 
region from May 1997 to April 2002 [2] and from October 2007 to December 
2010 [4] and was limited to three hospitals: MRCG Hospital, Edward Francis 
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Small Teaching Hospital, and World Evangelical Church Mission Hospital (Figure 1). Five other hos-
pitals that began to treat suspected meningitis cases in 2012 were included in the recent surveillance: 
Serekunda General Hospital, Brikama Health Centre, Fajikunda Health Centre, Bundung Maternal and 
Child Health Hospital, and Bwiam General Hospital (Figure 1). We assumed that all suspected meningi-
tis cases arising in WCR were admitted in these eight hospitals as there were no other hospitals in WCR 
that treated suspected meningitis cases. Vaccination status was determined from patient-held records or 
by the parents’ report.
Except for the addition of Real Time Polymerase Chain Reaction (RT-PCR) on cerebrospinal fluid (CSF), 
clinical and microbiological methods used in this surveillance were identical to previous surveillance 
[2,4,10]. A case of suspected meningitis was defined as a patient under-10 years of age, resident in WCR, 
and provisionally diagnosed as a case of meningitis by the admitting clinician. All suspected meningitis 
cases were admitted and managed according to national guidelines. CSF was collected for culture, Hib 
antigen detection by Latex Agglutination (LA), and RT-PCR. We attempted to collect blood samples for 
culture from all suspected meningitis cases. A case of Hib meningitis was defined as a suspected menin-
gitis case from whom Hib was detected in CSF by culture or LA or in blood by culture. We also defined 
Hib meningitis plus-PCR if Hib was detected in CSF by culture, antigen detection, or RT-PCR, or in blood 
by culture. All laboratory assays were performed at MRCG Fajara laboratories.
CSF culture and antigen detection by LA: For hospitals that were within one-hour drive from the MRCG labo-
ratories, CSF was collected without transport media. Where CSF could not be transported within an hour, 
it was inoculated into Trans Isolate Media [11], stored in a 37°C incubator, and transported to MRCG lab-
oratories within 48 hours. CSF culture was done using standard methods that remained unchanged from 
previous surveillance. Antigen detection by LA (DirectigenTM Meningitis Combo Test, Beckton Dickinson, 
Erembodegem, Belgium) was performed on CSF supernatants following the manufacturer’s instructions.
Blood culture: Blood culture used an automated Bactec system (Becton Dickinson, Sparks, USA). For alarm 
positive blood cultures, a 50-100μl aliquot of the specimen was inoculated onto Blood Agar, Chocolate 
Agar and MacConkey Agar plates, streaked, and incubated at 37°C with and without 5% CO
2
 for 24-48hrs 
for isolation of the causative agents of bacterial meningitis [12]. All suspected Hib growth on Chocolate 
Agar plates were confirmed by Oxidase test, X+V growth factor requirement, and serotyped using Hib 
antisera (Statens Serum Institute, Denmark).
RT-PCR: CSF for RT-PCR was transported to the MRCG laboratories within an hour. Otherwise, aliquots 
were stored at -20°C until transported. DNA was extracted from CSF as described by Carvalho et al 
[13]. The RT-PCR assay targeted the protein D-encoding gene (hpd) for detection of both typeable and 
non-typeable Haemophilus influenzae [14]. All detections with a cycle threshold ≤36 were considered pos-
itive. Valid results required proper functioning of controls and excluded data flagged by the QuantStu-
dioTM 7 Flex software (Thermo Fisher Scientific version 1.2). Hib serotype was identified by screening for 
the presence of the target gene bcsB, as previously described [14].
Figure 1. Map of Gambia showing the study sites, including the health facilities involved in Haemophilus influenzae 
type b (Hib) disease surveillance and Hib carriage studies.
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Surveillance in BHDSS
In May 2008, surveillance for invasive bacterial disease was established within BHDSS [15]. All individ-
uals with suspected meningitis, and all BHDSS residents aged ≥2months presenting at one of the health 
facilities in BHDSS with suspected pneumonia, sepsis, or meningitis were investigated. Surveillance con-
tinued 24 hours a day, 7 days a week. Case ascertainment used standardised criteria at each of the steps: 
(1) nurse screening for referral to a clinician, (2) surveillance diagnosis by a clinician and (3) investigation 
[16]. In contrast to WCR, blood culture was performed for all patients with suspected pneumonia, sepsis, 
or meningitis and lumbar puncture was done in cases of suspected meningitis. Aspiration of pleural fluid 
or lung aspiration was performed for selected patients. Vaccination status was determined from patient-held 
records until 2011 and thereafter this was recorded in an electronic database at the immunisation clinics.
Since 2013, patients with invasive bacterial disease have been tested for HIV by government services. We 
used an automated Bactec system to culture blood and a small proportion of samples collected at night 
in outlying clinics were cultured by traditional microbiological methods [16]. Other clinical samples 
were processed using standard methods that remained unchanged throughout the surveillance period 
[17]. Identification of Hib and other encapsulated Hi was done by slide agglutination using polyvalent 
and monovalent antisera to Hi types a, b, c, d, e and f (Beckton Dickinson, Erembodegem, Belgium). We 
defined a case of Hib disease as a patient with suspected pneumonia, sepsis, or meningitis from whom 
Hib was isolated from a normally sterile site. All samples were processed at the MRCG Basse laboratories. 
Laboratories in Basse and Fajara submitted to external QA procedures through the UK National External 
Quality Assessment Service (Sheffield, UK).
Carriage study
The carriage study was performed from July 2015 to November 2016. We aimed to collect oropharyngeal 
swabs (OPS) from 1000 children per age group (12-23 months, 2-7 years, and 8-16 years) with 500 from 
WCR and 500 from BHDSS. We calculated that this would provide 80% power to detect a hypothesised 
increase in carriage from 1% to 3% in children aged 12-23 months, and would provide precision of at 
least ±1% for all estimates. As there were no date of birth records for many school children, we enrolled 
them based on their class and grade level. For the pre-nursery children, OPS samples were collected from 
consecutive children attending immunisation clinics for measles vaccination at Serekunda Health Centre 
(SHC) in WCR and at Basse District Hospital (BDH) in BHDSS after obtaining written informed consent 
from primary carers. SHC and BDH are among the largest immunisation clinics located centrally in WCR 
and BHDSS respectively (Figure 1).
We used lists of nurseries and schools to enumerate children, starting with nurseries and schools locat-
ed closest to SHC or BDH and moved centrifugally until approximately equal numbers of children were 
identified in each grade (grades 1-4 for nurseries and 1-10 for schools). Study aims and procedures for 
collection of OPS were explained to the teachers and then to the children. OPS were collected from chil-
dren in the classrooms in presence of the teachers. Microbiological methods for the isolation and identi-
fication of Hib from OPS have been described elsewhere [4].
Statistical analysis
Incidence rates of Hib meningitis and Hib meningitis plus-PCR in WCR were estimated for 2015 and 
2016 and for the age groups 1 month-4 years and 5-9 years. Person-time for this analysis were calculated 
using 2013 WCR census data adjusted for estimated population growth [16].
The BHDSS analysis of incidence rates of Hib disease was limited to children 2-59 months of age who 
were resident in the BHDSS, and person-time was calculated using mid-year population estimates.
Carriage prevalence with exact 95% confidence intervals was calculated for age groups 12-23 months, 
2-7 years and 8-22 years, and estimates were compared using Fisher exact test. In all analyses, a statisti-
cal significance level of 5% was used.
Ethics
BHDSS and WCR surveillance, and the carriage study were approved by The Gambia Government/MRC 
Joint Ethics Committee (SCC/EC 1087, 1247; SCC/EC 1387; L2016/10).
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RESULTS
Surveillance in WCR
In WCR, 248 children were admitted with suspected meningitis from 24 December 2014 to 31 March 
2017 (Figure 2). The median age of suspected meningitis cases was 2.8 years (inter quartile range 
(IQR) = 10.0 months-6.0 years).
Using conventional microbiology, five Hib meningitis cases were detected. An additional 14 cases were 
detected by RT-PCR alone (Table 1). The median age differed among the cases detected by conventional 
microbiology (10.5 months, IQR = 10.1-10.8) and by RT-PCR alone (60.0 months, IQR = 14.5-81.0). Of 
19 cases with Hib meningitis plus-PCR, two (10%) were too young to be protected by vaccination. Of 17 
cases old enough to be protected by vaccination, seven (41%) were unvaccinated and two (12%) were 
under-vaccinated for their age. Of the seven unvaccinated cases, five were aged ≥5 years. Of the eight 
fully vaccinated cases, three were aged <2 years, three between two and four years, and two ≥5 years.
Three cases of Hib pneumonia were reported incidentally from the MRCG hospital where blood culture 
is normally done for cases of suspected invasive bacterial disease. These cases were not included in any 
analysis.
The incidence of Hib meningitis in those aged 1-59 months was 0.7 and 2.7 per 100 000 CY in 2015 and 
2016 respectively, similar to the incidence of 1.3 per 100 000 child years (CY) between 2008 and 2010 
as previously reported [4] (Figure 3, Panel A). Incidence was higher in under-5s compared to older chil-
dren. The median age of cases was 10.4 months (IQR = 10.1-10.8).
The incidence of Hib meningitis plus-PCR in 2015, among children aged 1 month-9 years was 4.1 per 
100 000 CY (Table 2). Incidence was higher in the under-5s compared to older children (P = 0.33). In 
2016, the incidence was 1.6 per 100 000 CY. As in 2015, incidence was higher in under-5s compared to 
older children (P = 0.02).
Surveillance in BHDSS
Surveillance enrolled 22 262 children who met criteria for referral and were assessed by clinicians. Of 
those children, 21 552 had a surveillance diagnosis of suspected pneumonia, sepsis, or meningitis and 
Figure 2. Flow of children with suspected meningitis investigated in Haemophilus influenzae type b disease surveil-
lance in the West Coast Region (WCR) of The Gambia from December 2014 to March 2017.
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21 315 had specimens collected for microbiological analysis. Twenty-five cases of Hib disease were de-
tected from 2008 to 2017 (Table 3). Their median age was five months (IQR = 3-15). Nine children 
(28%) were too young to be protected by vaccination. Of 16 children old enough to be protected by 
vaccination, five were under-vaccinated for their age, four with vaccine failure after three doses and 
five with vaccine failure after two doses. Of the four fully vaccinated children, three were aged <2 years 
and one was between two and four years of age. HIV was tested in eight cases or their mothers, and 
two mothers were found to be positive. Incidence of Hib disease peaked in 2012 and 2013 at 15.0 per 
100 000 CY (Figure 3, Panel B) but fell in 2014 and remained stable between 5.0 and 8.0 per 100 000 
CY from 2014 to 2017.
Hib Carriage
OPS were collected from 3157 children with a median age of 72.0 months (IQR = 20.5-121.8). Hib was 
isolated from eight children: one aged 1.2 years, one 4.5 years, and six between 8.1 and 17.1 years (Ta-
ble 4). Six (75%) of the eight children were fully vaccinated. Overall prevalence of carriage was 0.12% 
in WCR and 0.38% in BHDSS. Carriage increased significantly with age in BHDSS (P = 0.05) but not in 
WCR (P = 0.55).
DISCUSSION
We report the incidence of Hib meningitis over a 28-year period in WCR of The Gambia, the last 20 years 
of which saw the introduction of three primary doses of HCV without a booster into the EPI. Incidence of 
Hib meningitis in under-5s in WCR remained low at 0.7 and 2.7 per 100 000 CY for 2015 and 2016 re-
spectively, similar to incidence estimated in the same area using similar methods from 2008 to 2010 [3] 
and in 2001 and 2002 [2] (Figure 3, panel A). The results of this study substantiate long-term data from 
other African countries, which show that three primary doses of HCV without a booster have caused sub-
stantial and sustained declines in disease incidence. However, this study also adds data to other long-term 
population-based surveillance studies [18], which show that current vaccination strategies with three pri-
mary doses without a booster may not eliminate Hib transmission. Following the resurgence of Hib disease 
in BHDSS in 2012 and 2013, disease incidence fell to a stable level between 5.0 and 8.0 per 100 000 CY 
(Figure 3, Panel B). Carriage prevalence remains low at 0.2% in 12-23 months age group in WCR which 
Table 1. Characteristics of Haemophilus influenzae type b (Hib) meningitis cases in the West Coast Region (WCR) of The Gambia, ad-
mitted in health facilities from December 2014 to March 2017*
Admission 
yeAr
Admission 
month
Age 
(months) gender
number of hib 
vAccine doses
Age (months), 
1st dose†
Age (months), 
2nd dose†
Age (months), 
3rd dose† sAmples obtAined positive AssAys
outcome of 
hospitAlisAtion
2014 Dec 59 Male 3 2 3 4 CSF & Blood RT-PCR Recovered
2015 Jan 77 Male 3 3 5 6 CSF & Blood RT-PCR Recovered
2015 Feb 60 Male 0 CSF & Blood RT-PCR Died
2015 Mar 60 Male 0 CSF & Blood RT-PCR Died
2015 Mar 82 Male 3 2 3 5 CSF & Blood RT-PCR Recovered
2015 Mar 89 Female 0 CSF & Blood RT-PCR Recovered
2015 Mar 2 Female 1 2 CSF & Blood RT-PCR Recovered
2015 Apr 14 Male 3 10 12 12 CSF & Blood RT-PCR Recovered
2015 Apr 3 Male 2 2 3 CSF & Blood RT-PCR Recovered
2015 Apr 40 Male 3 2 3 4 CSF & Blood RT-PCR Recovered
2015 Jul 10 Female 1 2 CSF & Blood
Blood & CSF culture, 
Latex, RT-PCR
Recovered
2015 Jul 10 Male 3 2 3 4 CSF & Blood RT-PCR Recovered
2015 Jul 81 Female 0 CSF & Blood RT-PCR Recovered
2015 Aug 90 Female 1 53 CSF & Blood RT-PCR Recovered
2016 Mar 10 Female 0 CSF & Blood Latex & RT-PCR Recovered
2016 Apr 60 Male 0 CSF & Blood RT-PCR Recovered
2016 Aug 26 Male 3 2 3 4 CSF & Blood Blood culture Died
2016 Sep 10 Male 0 CSF & Blood Latex Recovered
2016 Sep 8 Male 3 2 3 4 CSF only Latex Recovered
RT-PCR – real time polymerase chain reaction, CSF – cerebrospinal fluid, Latex – latex agglutination
*Hib was detected in CSF by culture, antigen detection by Latex, or RT-PCR, or in blood by culture. No Hib meningitis cases were detected from Jan-
uary to March 2017.
†Dose of Hib vaccine.
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Figure 3. Incidence of Haemophilus influenzae type b (Hib). Panel A. Incidence of Haemophilus influenzae type b 
(Hib) meningitis in children under 5 years of age in the West Coast Region using conventional microbiology, 1990-
2016. Panel B. Incidence of Hib disease in children aged 2-59 months in the Basse Heath and Demographic Sur-
veillance System, 2008-2017.
Table 2. Incidence rates of Haemophilus influenzae type b (Hib) 
meningitis in the West Coast Region (WCR) of The Gambia 
by laboratory methods of diagnosis, calendar year, and age 
groups in 2015 and 2016
yeAr Age child-yeArs cAses* rAte (95% ci)†
Conventional microbiology‡ or RT-PCR of CSF:
2015 1m-4yrs 148 808 8 5.4 (2.3,10.6)
5-9yrs 165 114 5 3.0 (1.0,7.1)
1m-9yrs 313 922 13 4.1 (2.2,7.1)
2016 1m-4yrs 146 159 5 3.4 (1.1,8.0)
5-9yrs 165 317 0 0.0 (0.0,2.2)
1m-9yrs 311 476 5 1.6 (0.5,3.7)
Conventional microbiology only:
2015 1m-4yrs 148 808 1 0.7 (0.0,3.7)
5-9yrs 165 114 0 0.0 (0.0,2.2)
1m-9yrs 313 922 1 0.3 (0.0,1.8)
2016 1m-4yrs 146 159 4 2.7 (0.7,7.0)
5-9yrs 165 317 0 0.0 (0.0,2.2)
1m-9yrs 311 476 4 1.3 (0.3,3.3)
RT-PCR – real time polymerase chain reaction, CI – confidence interval, 
CSF – cerebrospinal fluid
* Hib meningitis cases. Excluding one case detected in December 2014.
†Rate per 100 000 child-years.
‡ Conventional microbiology: Hib was detected by culture of cerebro-
spinal fluid (CSF) or blood, or by antigen detection by latex aggluti-
nation of CSF.
is similar to previously reported estimates of 0.9% in 2009 [4] 
and 0.3% in 2002 [2].
Incidence of Hib meningitis in WCR was higher when we in-
cluded additional Hib meningitis cases identified by RT-PCR 
(5.4 and 3.4 per 100 000 CY for 2015 and 2016 respective-
ly) (Table 2). Of a total of 22 cases only eight were detected 
without the use of PCR and PCR yielded 14 additional cas-
es. PCR is a sensitive and specific diagnostic tool that may be 
valuable in populations with high pre-hospital antibiotic use. 
In a recent study of 411 children presenting with suspected 
sepsis or severe focal infections in the largest referral hospital 
in The Gambia, 80% reported prehospital antibiotic use [19]. 
Indeed, the use of PCR should be considered to increase the 
sensitivity of any surveillance for Hib disease.
Our findings of Hib meningitis incidence of 4.0-5.0 per 
100 000 CY in WCR and Hib disease incidence of 5.0-8.0 per 
100 000 CY in BHDSS represent greater than 90% reductions 
from pre-vaccine Hib meningitis incidence of 60.0-70.0 per 
100 000 CY (Figure 3). Similar vaccine impact in settings us-
ing a three dose primary schedule without a booster have been 
described in Kenya [18], Chile, Colombia [20], and Mongolia 
[21]. In all these settings the estimated incidence of Hib dis-
ease in the under-5-year age group three or more years after 
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vaccine introduction was <2.0 per 100 000 CY. Hib disease is uncommon in these settings because of the 
effectiveness of Hib vaccination with three primary doses without a booster.
Despite the undoubted impact of Hib vaccination in our setting, detection of ongoing Hib cases and re-
ports of Hib mortality globally [1] are concerning. More rapid waning of immunity associated with the 
use of three primary doses without a booster is one reason to consider the use of booster doses. Our data, 
however, indicate that the disease in The Gambia is associated with other factors that may be amenable to 
public health intervention. Of the WCR cases over two years of age, five were unvaccinated, five were ful-
ly vaccinated, and one received only one dose, indicating that waning immunity and unvaccinated status 
were both similarly associated with disease. In BHDSS, only one case occurred in fully vaccinated cases 
older than two years of age.
Rather than waning immunity, Hib cases were also related to issues of coverage and timeliness. Thirty-sev-
en percent of all the cases in WCR (n = 19) and 36% in BHDSS occurred in unvaccinated children. These 
Table 4. Prevalence of Haemophilus influenzae type b (Hib) carriage in 2015/2016 by region of The Gambia and age 
groups
region Age groups gender (% mAle) number swAbbed number with hib cArriAge prevAlence of cArriAge (%) (95% cl)
WCR
12-<24 months 49 503 1 0.20 (0.005-1.1)
2-7 years 51 537 0 0 (0-0.7) *
≥8 years 43 532 1 0.19 (0.005-1.0)
BHDSS
12-<24 months 52 491 0 0 (0-0.75) *
2-7 years 48 542 1 0.18 (0.005-1.0)
≥8 years 48 552 5 0.91 (0.30-2.1)
CI – confidence interval, WCR – West Coast Region, BHDSS – Basse Health and Demographic Surveillance System
*One-sided, 97.5% confidence interval
Table 3. Characteristics of children aged 2-59 months with Haemophilus influenzae type b (Hib) disease resident in the Basse Health 
and Demographic Surveillance System (BHDSS), Upper River Region, The Gambia, admitted in health facilities from 2008 to 2017
Admission 
yeAr
Admission 
month
Age 
(months) gender
number of hib 
vAccine doses
Age (months), 
1st dose*
Age (months), 
2nd dose*
Age (months), 
3rd dose* positive sAmples
outcome of 
hospitAlisAtion
hiv test
2010 Jul 29 Male 0 Blood Recovered ND
2011 Jun 3 Male 1 3 CSF & Blood Died ND
2011 Aug 2 Female 0 CSF & Blood Recovered ND
2011 Apr 15 Male 3 1 3 5 CSF & Blood Recovered ND
2011 Oct 11 Female 3 2 4 6 LA Recovered ND
2012 Jul 22 Female 3 1 5 5 Blood Died ND
2012 Sep 54 Female 0 Blood Not admitted ND
2012 Oct 4 Female 2 2 4 CSF & Blood Discharged ND
2012 Nov 48 Male 0 Blood Discharged ND
2012 Jun 5 Female 2 NA Blood Recovered ND
2013 Jan 48 Female 0 CSF & Blood Discharged ND
2013 Feb 3 Female 1 2 Blood Discharged Mo
2013 Apr 2 Female 0 Blood Discharged ND
2013 May 2 Female 0 Blood Discharged ND
2013 Oct 14 Female 0 Blood Died Mo
2014 Feb 2 Female 0 Blood Discharged ND
2014 Sep 3 Female 1 2 Blood Discharged Mo
2015 Apr 5 Female 2 3 5 Blood Not admitted Mo
2015 Jul 6 Male 2 4 6 Blood Discharged ND
2015 Aug 38 Male 3 2 3 4 Blood Discharged Inf
2016 Mar 4 Male 1 3 Blood Died Mo
2016 Sep 2 Male 1 2 Blood Discharged Mo
2017 Jan 11 Female 1 NA Blood Recovered ND
2017 Jun 3 Female 1 NA CSF & Blood Recovered ND
2017 Oct 4 Female 2 3 4 Blood Recovered Mo
NA – not available, CSF – cerebrospinal fluid, LA – lung aspirate, ND – not done, Mo – mother’s HIV test result, Inf – infant’s HIV test result
*Dose of Hib vaccine.
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children were Gambian residents at the time of illness, although some had migrated to The Gambia and 
were not vaccinated in their country of birth. Our data indicate that indirect protection offered by high 
coverage of three primary doses does not completely protect these unvaccinated children. Children who 
do not present for vaccination, and those who migrate after 12 months of age, represent a challenge to the 
EPI. Strategies to identify and give missed doses at visits when routine vaccination is not given could be 
considered. Similarly, promoting the value of vaccination and increasing access to care may increase cov-
erage in households that are difficult to reach. Addressing the timeliness of vaccination is challenging in 
our setting where most vaccinations are delivered at mobile clinics that visit small geographic catchment 
areas on a monthly basis.
Delayed vaccination was associated with a greater number of cases than being unvaccinated. Of 17 cas-
es in WCR, and 16 in BHDSS who were old enough to be protected by the 2, 3, 4-month schedule, the 
first or second doses were delayed for two in WCR and eight in BHDSS. In WCR, two cases, at 2.7 and 
3.7 months of age, occurred before the age at which children could be protected by the current sched-
ule. In BHDSS nine of 25 cases were too young to be protected by vaccination and five were aged 3 or 
4 months. To prevent Hib cases at 3 or 4 months of age, the EPI could transition to scheduling at 6, 10, 
and 14 weeks of age as in neighbouring Senegal [22], or even 1, 2, and 3 months of age as in Papua New 
Guinea [22] to maximise individual level protection, but there is no empirical data to assess the added 
benefit of early primary dosing at population level.
A notable finding of this study was that the median age of Hib cases in WCR was 3.4 years, which is in 
contrast to the median age of <1 year seen both in previous WCR surveillance reports [4,10] and the 
BHDSS. Hib disease in older children in a population with low carriage is difficult to explain. We may be 
observing a shift in the epidemiology of Hib disease in The Gambia, and this must be closely watched. It 
is also possible that there were upward shifts in the age distribution of cases in the previous surveillance 
in WCR (2008-2010) and BHDSS, but insensitive conventional microbiology tests were unable to cap-
ture all cases, the majority of which might have been >1 year of age.
It is not clear why the resurgence of the Hib disease occurred in BHDSS. Potential explanations include 
increased acquisition of Hib by older children due to their waning immunity and subsequent transmission 
to younger unvaccinated/partially vaccinated children, temporal changes in the circulation of respirato-
ry viruses associated with bacterial pneumonia, or cross border migration of poorly vaccinated popula-
tions. It may also be that the increase in Hib cases in BHDSS was a chance finding associated with small 
numbers of cases and unstable year-to-year estimates. It does not appear that changes in the prevalence 
of HIV infection had a role. The BHDSS surveillance, which does include older children and adults, de-
tected only two older cases, one in a 10-year-old in 2012 and the other in a 5-year-old in 2013. Low sus-
ceptibility and less intense interaction (due to poor schooling rates) among older children in the rural 
setting may explain low Hib disease rates.
The prevalence of carriage (carriage) was very low in younger age groups and was similar to previous sur-
veillance. However, it was not clear why carriage was relatively higher (0.91%) in older children in BHDSS. 
Nonetheless, carriage <1% among older children does not indicate a specific age group responsible for 
Hib transmission in the population. Low carriage among older children is consistent with observations 
elsewhere [18] indicating the schedule of three primary doses without a booster can exert substantial in-
direct effects. An earlier Gambian study showed significantly higher concentrations of Hib antibodies in 
children in urban areas compared to those living in rural areas, and antibody concentrations were sig-
nificantly lower in older compared to younger children [4]. These two factors could explain the relatively 
higher carriage in older children in the rural BHDSS. HIV infection is unlikely to be driving Hib carriage 
in The Gambia since HIV prevalence is very low. Relatively higher carriage observed in older children 
in the BHDSS might have served as a reservoir of Hib infection for transmission to younger children re-
sulting in the resurgence of invasive Hib disease in 2012 and 2013. However, the overall low carriage in 
BHDSS is evidence that the current schedule is associated with good herd immunity.
This study had some limitations. We could not include Hib cases with pneumonia or septicaemia in WCR 
because of inadequate resources in the hospitals. This limitation has been consistent across the surveil-
lance periods evaluating the impact of the introduction of Hib vaccination in WCR. However, it is also 
true that surveillance for Hib pneumonia is difficult due to challenges in implementing a standardised 
definition for pneumonia and due to low yield of blood cultures from patients with pneumonia. Surveil-
lance for Hib meningitis is somewhat more efficient because CSF from patients with suspected meningi-
tis will be positive more often than blood cultures from patients with pneumonia. Thus, use of menin-
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gitis as an endpoint is less sensitive to ascertainment bias. Another limitation was not selecting children 
for the carriage study as a random sample of the population. Nevertheless, these children came from the 
same population from which the cases arose, and school-based sampling is an accepted survey method 
[23]. We could not exclude the possibility of the emergence of a hypervirulent Hib strain that might have 
caused Hib disease since we have not genotyped all the isolates. However, any hypervirulent stains were 
not detected in an earlier study investigating the re-emergence of Hib disease following its elimination [3].
A strength of the study was its ability to estimate incidence in WCR and BHDSS. A further strength of 
the study was the use of consistent surveillance methods in WCR allowing comparison with earlier sur-
veillance in 2001 and 2002, and from 2008 to 2010, and continuous observation in the BHDSS from 
2008 to 2017.
Taken together, these data suggest that three primary doses of Hib vaccine in infants without a booster is 
effective in sustaining the control of Hib disease in The Gambia. However, the sustained low incidence of 
disease in this population is a concern for the risk of a future upsurge and for the failure to eliminate the 
disease. Experience from the UK suggests that there are settings where a booster dose is needed to sus-
tain reductions in Hib disease. However, our data were insufficient to indicate the use of a booster dose. 
There is little experience of a booster dose in resource poor settings such as The Gambia. South Africa 
introduced a booster dose in 2010, 11 years after introduction of three primary series of Hib vaccine, but 
this was not in response to low Hib antibody titres but rather due to the introduction of a combination 
vaccine including inactivated polio vaccine [24]. Before the introduction of the booster in South Africa, 
an increase in Hib disease incidence was noted over several years, although this increase was small and 
disease incidence remained within the range reported from other countries.
Interventions to further control of Hib disease in our setting would aim to improve coverage – catch-up 
missed doses, engage hard to reach households and migrants, and improve the timeliness of the first and 
second doses of Hib vaccine. In addition, continued surveillance is needed to monitor whether effective 
control of disease is sustained or whether shifts in epidemiology (eg, disease occurring in older children 
and fewer opportunities for natural boosting) will necessitate a booster dose. Information about Hib dis-
ease epidemiology in The Gambia with long term use of HCV can inform recommendations for Hib vac-
cination schedules in similar settings. In the UK, an increase in vaccine failure 8 years after the introduc-
tion of routine vaccination was at least partly caused by a greater than expected decline in Hib antibody 
response following a schedule without a booster dose. Therefore, we also need to undertake studies peri-
odically to confirm long-term immunity by monitoring Hib antibody response and carriage.
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